---
layout: default
title: Pitavastatin Calcium
parent: 僅模型預測 (L5)
nav_order: 230
evidence_level: L5
indication_count: 0
---

# Pitavastatin Calcium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pitavastatin Calcium: Drug Repurposing Evaluation — Insufficient Data to Complete Prediction

## One-Sentence Summary

Pitavastatin Calcium is a statin-class lipid-lowering agent, clinically established for the management of hypercholesterolaemia and mixed dyslipidaemia through inhibition of HMG-CoA reductase.
No TxGNN repurposing predictions were generated for this drug in the current evidence pack, making it impossible to identify or evaluate a candidate new indication.
All three major data components — mechanism of action, safety labelling, and product-level NPRA registration details — remain unresolved data gaps; the pipeline must be re-run with complete inputs before a full evaluation can be produced.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Hypercholesterolaemia / Dyslipidaemia *(inferred from drug class; NPRA-specific approved text not retrieved)* |
| Predicted New Indication | — *(No TxGNN prediction available in this evidence pack)* |
| TxGNN Prediction Score | — |
| Evidence Level | — *(No prediction to evaluate)* |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN-predicted indication is present in the current evidence pack (`predicted_indications` array is empty). A structured repurposing rationale cannot be constructed without a target disease.

Based on publicly available information, Pitavastatin Calcium is a synthetic, fully fluorinated statin that competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase — the rate-limiting enzyme in hepatic cholesterol biosynthesis. By reducing intracellular cholesterol, it upregulates LDL receptors, lowers circulating LDL-C and triglycerides, and modestly raises HDL-C. Beyond lipid effects, statins as a class also exert pleiotropic actions including anti-inflammatory, antioxidant, and immunomodulatory effects, properties that have motivated repurposing research in oncology, cardiovascular risk reduction beyond lipid-lowering, and neurodegenerative diseases.

However, all of the above is general class knowledge, not evidence drawn from this evidence pack. The formal mechanism of action data field (`original_moa`) is flagged as a data gap (severity: High), and no indication-level evidence (clinical trials or literature) has been retrieved. Once TxGNN predictions and supporting evidence are loaded into the pack, a complete mechanism-to-indication alignment analysis can be performed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication is available in this evidence pack to query against.

---

## Literature Evidence

Currently no related literature available — no predicted indication is available in this evidence pack to query against.

---

## Malaysia Market Information

The evidence pack records **3 registered products** in Malaysia, but all product-level detail fields (authorisation number, product name, dosage form, and approved indication text) were not populated during data retrieval. The table below reflects the state of the data as received.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|-------------|-------------|---------------------|
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |
| Not retrieved | Not retrieved | Not retrieved | Not retrieved |

> **Note:** NPRA product registration details should be retrieved directly from the [NPRA Quest 3+ portal](https://quest3plus.bpfk.gov.my) or via package insert PDF parsing to populate these fields.

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields — key warnings, contraindications, and drug-drug interactions — are flagged as data gaps in this evidence pack. The blocking data gap (DG001) indicates that TFDA/NPRA package insert PDFs have not yet been downloaded and parsed. This must be resolved before any safety-based prescribing or repurposing decision can be made.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack for Pitavastatin Calcium contains no TxGNN repurposing predictions and is missing all three critical data layers (MOA, safety labelling, and NPRA product details); no repurposing candidate can be evaluated, scored, or recommended at this stage.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** with Pitavastatin Calcium correctly mapped to its DrugBank ID (DB08860) so that `predicted_indications` is populated with candidate diseases, scores, and supporting evidence
- **Resolve DrugBank data gap (DG002):** Query the DrugBank API using DrugBank ID DB08860 to retrieve the full drug profile including pharmacology, MOA, drug categories, and toxicity data
- **Resolve NPRA/TFDA package insert data gap (DG001):** Download and parse the product insert PDFs from the NPRA portal or TFDA website to populate key warnings, contraindications, approved indication texts per registration, and drug interaction data
- **Populate NPRA licence details:** Re-query the NPRA Quest 3+ database to retrieve authorisation numbers, product names, dosage forms, and manufacturers for all 3 registered products
- **Re-generate evidence pack** once the above gaps are resolved, then produce a full evaluation report with a defined target indication, evidence level, and Go/Proceed/Hold recommendation grounded in actual data
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

